M Grundman

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patients
    Ming Ji
    Division of Epidemiology and Bisotatistics, Graduate School of Public Health, San Diego State University, 5500 Campanile Drive, San Diego, CA 92182 4162, USA
    J Alzheimers Dis 5:375-82. 2003
  2. ncbi Vitamin E and Alzheimer disease: the basis for additional clinical trials
    M Grundman
    Alzheimer s Disease Cooperative Study, 9500 Gilman Drive 0949, La Jolla, CA, 92093 0949, USA
    Am J Clin Nutr 71:630S-636S. 2000
  3. ncbi Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
  4. ncbi Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla 92093 0949, USA
    J Mol Neurosci 20:241-8. 2003
  5. ncbi A phase I study of AIT-082 in healthy elderly volunteers
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla 92037, USA
    J Mol Neurosci 18:283-93. 2002
  6. ncbi Antioxidant strategies for Alzheimer's disease
    Michael Grundman
    Alzheimer s Disease Cooperative Study, University of California, San Diego, 8950 Villa La Jolla Drive, Suite 2200, La Jolla, California 92037, USA
    Proc Nutr Soc 61:191-202. 2002
  7. ncbi Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla, USA
    J Mol Neurosci 19:23-7. 2002
  8. ncbi A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients
    M Grundman
    Department of Neurosciences, University of California San Diego, 9500 Gilman, La Jolla, CA 92093, USA
    Life Sci 73:539-53. 2003
  9. ncbi Donepezil delays progression to AD in MCI subjects with depressive symptoms
    P H Lu
    Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 72:2115-21. 2009
  10. ncbi Report of the task force on designing clinical trials in early (predementia) AD
    P S Aisen
    Department of Neurosciences, UCSD, 9500 Gilman Drive M C 0949, La Jolla, CA 92093, USA
    Neurology 76:280-6. 2011

Detail Information

Publications29

  1. ncbi Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patients
    Ming Ji
    Division of Epidemiology and Bisotatistics, Graduate School of Public Health, San Diego State University, 5500 Campanile Drive, San Diego, CA 92182 4162, USA
    J Alzheimers Dis 5:375-82. 2003
    ..Our finding supports the clinical belief of the existence of a change point during cognitive decline among AD patients and suggests the use of change point models for the longitudinal modeling of cognitive decline in AD research...
  2. ncbi Vitamin E and Alzheimer disease: the basis for additional clinical trials
    M Grundman
    Alzheimer s Disease Cooperative Study, 9500 Gilman Drive 0949, La Jolla, CA, 92093 0949, USA
    Am J Clin Nutr 71:630S-636S. 2000
    ..A new clinical trial is planned that will examine whether vitamin E can delay or prevent a clinical diagnosis of Alzheimer disease in elderly persons with mild cognitive impairment...
  3. ncbi Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
    ..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
  4. ncbi Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla 92093 0949, USA
    J Mol Neurosci 20:241-8. 2003
    ..We conclude that the relationship between hippocampal volume and risk of AD is likely tied to reduced memory performance and not associated with impairment in nonmemory cognitive domains...
  5. ncbi A phase I study of AIT-082 in healthy elderly volunteers
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla 92037, USA
    J Mol Neurosci 18:283-93. 2002
    ..In conclusion, AIT-082 was rapidly absorbed by the oral route with a half-life suitable for once daily dosing. No problems with tolerability or safety were demonstrated...
  6. ncbi Antioxidant strategies for Alzheimer's disease
    Michael Grundman
    Alzheimer s Disease Cooperative Study, University of California, San Diego, 8950 Villa La Jolla Drive, Suite 2200, La Jolla, California 92037, USA
    Proc Nutr Soc 61:191-202. 2002
    ..Nevertheless, the clinical value of these agents for AD prevention and treatment is ambiguous, and will remain so until properly designed human trials have been performed...
  7. ncbi Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial
    Michael Grundman
    Department of Neurosciences, University of California, San Diego, La Jolla, USA
    J Mol Neurosci 19:23-7. 2002
    ..In summary, these data suggest that MRI hippocampal volume may be a useful correlate of disease severity in MCI subjects and a prognostic indicator of subsequent AD...
  8. ncbi A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients
    M Grundman
    Department of Neurosciences, University of California San Diego, 9500 Gilman, La Jolla, CA 92093, USA
    Life Sci 73:539-53. 2003
    ..No problems with tolerability or safety were found. AIT-082 appears suitable for testing in larger clinical trials for the treatment of AD and other neurologic disorders...
  9. ncbi Donepezil delays progression to AD in MCI subjects with depressive symptoms
    P H Lu
    Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 72:2115-21. 2009
    ..To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship...
  10. ncbi Report of the task force on designing clinical trials in early (predementia) AD
    P S Aisen
    Department of Neurosciences, UCSD, 9500 Gilman Drive M C 0949, La Jolla, CA 92093, USA
    Neurology 76:280-6. 2011
    ..The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia...
  11. ncbi Prevalence of symptoms on the CERAD behavior rating scale for dementia in normal elderly subjects and Alzheimer's disease patients
    R E Tractenberg
    Department of Neurosciences, University of California, San Diego 92093 0949, USA
    J Neuropsychiatry Clin Neurosci 12:472-9. 2000
    ..The authors conclude that assessment of behavior in long-term studies will be needed to quantify "abnormal" levels, and that item-level BRSD information could be important in clinical trials...
  12. ncbi Estrogen levels do not correlate with improvement in cognition
    Leon J Thal
    Department of Neurosciences, University of California, San Diego, School of Medicine, 9500 Gilman Dr, La Jolla, CA 92093, USA
    Arch Neurol 60:209-12. 2003
    ..To investigate whether an association exists between estradiol and estrone levels and measures of cognitive functioning in women with Alzheimer disease (AD) treated with conjugated equine estrogen (Premarin; Wyeth-Ayerst, Philadelphia, Pa)...
  13. ncbi Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment
    Adam Fleisher
    Department of Neurosciences, University of California San Diego, La Jolla, Calif, USA
    Arch Neurol 62:953-7. 2005
    ..The presence of the apolipoprotein E epsilon4 (APOE*E4) allele has been associated with greater hippocampal atrophy in women than in men with Alzheimer disease. This relationship has not been demonstrated in MCI...
  14. ncbi Is there a rationale for including only patients already being treated with acetylcholinesterase inhibitors in a prodromal AD trial?
    M Grundman
    Global R and D Partners, LLC, San Diego, CA, USA
    J Nutr Health Aging 16:336-8. 2012
    ....
  15. ncbi Idebenone treatment fails to slow cognitive decline in Alzheimer's disease
    L J Thal
    Department of Neurosciences, University of California San Diego School of Medicine, La Jolla 92093 0624, USA
    Neurology 61:1498-502. 2003
    ..To determine the effect of idebenone on the rate of decline in Alzheimer's disease (AD)...
  16. ncbi Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study
    R A Mulnard
    Institute for Brain Aging and Dementia, University of California, Irvine 92697 4540, USA
    JAMA 283:1007-15. 2000
    ..Several reports from small clinical trials have suggested that estrogen replacement therapy may be useful for the treatment of Alzheimer disease (AD) in women...
  17. ncbi 2012: A watershed year for Alzheimer's disease research
    M Grundman
    Global RandD Partners, LLC, San Diego, CA, USA
    J Nutr Health Aging 17:51-3. 2013
    ....
  18. ncbi A quarter century of advancing treatment for Alzheimer's disease with Leon J. Thal
    Michael Grundman
    Alzheimer's Disease Clinical Development Program, Elan Pharmaceuticals, Inc, San Francisco, CA, USA
    Alzheimers Dement 4:S51-5. 2008
  19. ncbi Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    JAMA 289:2819-26. 2003
    ....
  20. ncbi A neuropsychological test battery for use in Alzheimer disease clinical trials
    John Harrison
    CPC Pharma Services, PO Box 3223, Warminster, Wiltshire BA12 8XA, England
    Arch Neurol 64:1323-9. 2007
    ....
  21. ncbi Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI
    Clifford R Jack
    Department of Radiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Neurobiol Aging 29:1285-95. 2008
    ..000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI...
  22. ncbi Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia
    Charles DeCarli
    Department of Neurology and Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California at Davis, Sacramento 95817, USA
    Arch Neurol 64:108-15. 2007
    ..Prognostic uncertainty suggests the need for additional measures to assist the clinician...
  23. ncbi Vitamin E and donepezil for the treatment of mild cognitive impairment
    Ronald C Petersen
    Mayo Clinic College of Medicine, Rochester, Minn, USA
    N Engl J Med 352:2379-88. 2005
    ....
  24. ncbi A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease
    Clifford Singer
    Department of Psychiatry, Oregon Health and Science University, Portland, USA
    Sleep 26:893-901. 2003
    ..To determine the safety and efficacy of 2 dose formulations of melatonin for the treatment of insomnia in patients with Alzheimer's disease...
  25. ncbi A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease
    Dale B Schenk
    Elan Pharmaceuticals, San Francisco, CA 94080, USA
    Neurodegener Dis 2:255-60. 2005
    ..These findings have led to newer alternative A beta immunotherapy approaches that include both active and passive approaches that are currently in clinical testing in both the USA and Europe...
  26. ncbi Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis
    Michael Pride
    Wyeth Research, Collegeville, PA 19426, USA
    Neurodegener Dis 5:194-6. 2008
    ..In a phase 2a clinical trial of AN1792 (Study 201), a potential immunotherapeutic agent for use in Alzheimer's disease (AD), approximately 6% of the treated AD patients (18/300) developed meningoencephalitis (ME)...
  27. ncbi Laboratory investigations and treatment in frontotemporal dementia
    Florence Pasquier
    CHRU Clinique Neurologie, Lille. France
    Ann Neurol 54:S32-5. 2003
  28. ncbi NSAIDs and hypertension
    Paul S Aisen
    Arch Intern Med 163:1115; author reply 1115-6. 2003
  29. ncbi Weight loss in the elderly may be a sign of impending dementia
    Michael Grundman
    Arch Neurol 62:20-2. 2005